MARLBOROUGH, Mass.,
Aug. 15, 2019 /PRNewswire/
-- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology
company developing the next generation of immuno-oncology
therapeutics based on its proprietary self-delivering RNAi
(sd-rxRNA®) therapeutic platform, announced today that
is has entered into a research collaboration with the Helmholtz
Zentrum München. The agreement covers the design and development of
new targets based on Phio Pharmaceuticals' proprietary
self-delivering RNAi platform for use in cancer
immunotherapies. This work will be performed at the
Immunoanalytics Core Facility & research group under leadership
of Prof. Dr. Elfriede Nößner and will complement Phio
Pharmaceuticals' internal research and development activities and
collaborations with various other academic and industry
partners.
Logo -
https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Dr. John A. Barrett, Chief
Development Officer of Phio Pharmaceuticals, stated: "We are
excited to be working with Dr. Nößner and her team who are experts
in the study of lymphoid and myeloid effector cells and how to
improve their contribution in overcoming tumor immunosuppression.
In addition, the group has a successful track record of industry
collaborations, thus the work will be of direct relevance for the
development of the next generation therapeutics based on our
self-delivering RNAi platform."
Prof. Dr. Elfriede Nößner, Head of Immunoanalytics at the
Helmholtz Zentrum München, said: "Available data shows that Phio
Pharmaceuticals' self-delivering RNAi technology is ideally suited
to inhibit checkpoints in immune effector cells such as T cells and
NK cells in the microenvironment of solid tumors or inflammatory
diseases. I look forward to working with the Phio team on targets
beyond their interesting checkpoint-inhibiting self-delivering RNAi
pipeline."
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology
company developing the next generation of immuno-oncology
therapeutics based on its self-delivering RNAi
(sd-rxRNA®) therapeutic platform. The Company's efforts
are focused on silencing tumor-induced suppression of the immune
system through our proprietary sd-rxRNA platform with utility in
immune cells and/or the tumor microenvironment. Our goal is
to maximize the power of our sd-rxRNA therapeutic compounds by
weaponizing immune effector cells to overcome tumor immune escape
providing patients with a powerful new treatment option that goes
beyond current treatment modalities. For additional information,
visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are neither historical facts nor
assurances of future performance. These statements are based only
on our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements
as a result of a number of important factors, including, but not
limited to, the safety and efficacy of our product candidates,
future success of our clinical trials and scientific studies,
expected duration of available cash runway, our ability to enter
into strategic partnerships and the future success of these
strategic partnerships, the availability of funds and resources to
pursue our research and development projects and general economic
conditions. Our Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q include detailed risks under the caption "Risk
Factors" that may affect our business, results of operations and
financial condition. Readers are urged to review these risk factors
and to not act in reliance on any forward-looking statements, as
actual results may differ from those contemplated by our
forward-looking statements. Phio does not undertake to update
forward-looking statements to reflect a change in its views, events
or circumstances that occur after the date of this release.
Contact
Phio Pharmaceuticals Corp.
ir@phiopharma.com
View original
content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-and-helmholtz-zentrum-munchen-to-collaborate-on-novel-targets-for-the-use-of-self-delivering-rnai-in-t-cell-and-nk-cell-adoptive-cell-therapy-therapeutics-300901990.html
SOURCE Phio Pharmaceuticals Corp.